Bone Abstracts

C-C chemokine receptor 5 (CCR5) is a co-receptor of macrophage-tropic viruses including HIV. Epidemiological and pathological findings have reported that functional changes in CCR5 correlate with HIV transmission bone destruction disease. However, the roles of CCR5 in bone pathophysiology have not been well documented.Ccr5-deficient osteoclasts showed decreased bone resorption activity accompanied with disorganized cellular architecture and impa...

Backgrounds: Ossification of the posterior longitudinal ligament (OPLL) is characterized by pathological ectopic ossification of the posterior longitudinal ligament. Development of OPLL induces compression myelopathy or radiculopathy by spinal stenosis and the loss of spinal flexibility by ankylosing spinal hyperosteosis (ASH). Although the etiology of OPLL has not been fully elucidated, systemic and local bone formation factors may play a role in the pathogenesis of OPLL. The...

Purpose: This combined qualitative and quantitative study aimed to investigate women’s personal reasons for and choices to decline the screening for osteoporosis. The ROSE study is a randomized prospective population-based trial investigating the efficacy of a screening program to prevent fractures in women aged 65–80 years.Methods: A triangulated approach combining data from interviews and questionnaire. 7020 questionnaires from the screening ...

The formation of skeletal muscle depends on myogenic regulatory factors of the MyoD family that are essential for entry into the myogenic programme and subsequent differentiation of muscle fibres. More recently attention has focussed on upstream regulators of muscle progenitor cells, prior to activation of the myogenic determination genes Myf5 and MyoD. In this context, Pax3 and Pax7 play an important role. In the embryo, Pax3 marks muscle stem cells that give rise to trunk an...

Tumour necrosis factor receptor associated factors (TRAFs) play a key role in signal transduction in mammalian cells. Several members of the TRAF family have been identified but only TRAF2 and TRAF6 are implicated in the regulation of osteoclastogenesis. Here we studied the role of TRAF2 and TRAF6 in breast cancer induced bone cell activity and osteolysis. We observed that TRAF2, but not TRAF6, is highly expressed in the human MDA-MB-231 (MDA-231) bone-seeking breast cancer ce...

The oim/oim mouse resembles type III OI. Our study mimics clinical questions: is RANK-Fc as efficacious as ALN in reducing fracture number? Is RANK-Fc safe to administer to children? Is there any advantage to receiving RANK-Fc treatment post adolescence, following no treatment or ALN treatment from infancy through adolescence?All animal work was done under an IACUC-approval. Mice – n=200, WT or oim/oim. Treatment spanned a...

Radiographs of the second metacarpal are used to assess bone strength development in paediatric populations. Children with achondroplasia and osteogenesis imperfecta (OI) have known differences in bone strength. Details of how bone strength develops and compares within these populations to unaffected children are lacking. A data set for patients with achondroplasia and OI was established.A retrospective IRB-approved review of bone-age films (n=6...

Objective: The purpose of this study was to determine whether osteogenesis imperfecta (OI) patients entering adulthood should continue with bisphosphonate therapy or would benefit from switching to a RANKL blockade therapy. To address this question, we used a mouse model of type III OI.Methods: Animal studies were performed under IACUC approval. OI (oim/oim) and wild-type (WT) mice were treated from 2–26 weeks with i) saline; ii) alendronat...

Objective: The purpose of this ongoing study was to determine whether osteogenesis imperfecta (OI) patients entering adulthood should continue with bisphosphonate therapy or would benefit from switching to a RANKL blockade therapy. To address this question, we used a mouse model of type-III OI.Methods: Under IACUC-approval, +/+ and oim/oim mice were treated from 2–26 weeks (n=20/treatment/genotype) with either 1) saline 24 weeks; 2...

Tumour necrosis factor receptor-associated factor 6 (TRAF6) plays a key role in osteoclastogenesis through the regulation of RANK/CD40 TRAF6-mediated signaling. Mice deficient in TRAF6 exhibit high bone mass and were protected against inflammation-induced bone loss. Here we describe the effects of a small-molecule 6877002 that has been shown to prevent the binding of TRAF6 to its domain on RANK/CD40 receptor on osteoclast formation in vitro and in vivo and on...